Published in J Leukoc Biol on January 19, 2011
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol (2011) 1.30
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol (2012) 0.91
Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol Immunother (2011) 0.88
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies (Basel) (2012) 0.86
Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol (2012) 0.86
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol (2015) 0.85
In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res (2016) 0.82
Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis. J Proteomics (2013) 0.80
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol (2015) 0.79
Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol (2016) 0.79
(19)F-MRI for monitoring human NK cells in vivo. Oncoimmunology (2016) 0.78
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine (Lond) (2015) 0.75
Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Front Immunol (2017) 0.75
Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science (1989) 5.08
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A (1985) 4.19
A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization. Cell (1989) 3.70
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol (1996) 2.68
High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J Exp Med (1986) 2.37
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol (2004) 2.16
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood (1998) 1.64
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood (1998) 1.56
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A (1992) 1.51
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res (2004) 1.46
Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem (2003) 1.39
Receptor-mediated endocytosis of interleukin 2 in a human tumor T cell line. Degradation of interleukin 2 and evidence for the absence of recycling of interleukin receptors. J Biol Chem (1986) 1.25
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res (1987) 1.21
Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother (2008) 1.13
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res (1996) 1.10
Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci (1978) 1.09
Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci U S A (1989) 1.07
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01
Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res (2001) 0.98
Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res (2009) 0.97
Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother (2004) 0.95
Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol (1991) 0.94
Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res (1986) 0.94
Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine. Methods Mol Med (2003) 0.93
Intracellular pathway of interleukin 2 following receptor-mediated endocytosis. Eur J Immunol (1986) 0.92
The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res (2001) 0.91
Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother (1999) 0.90
Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies. Anticancer Res (1994) 0.88
The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res (2008) 0.86
GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer (2001) 0.85
Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common gamma-chain and a lymphoid cell environment. J Immunol (2000) 0.82
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother (2005) 0.81
Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors. Exp Toxicol Pathol (2000) 0.79
Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Pigment Cell Res (1992) 0.77
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest (2006) 3.77
T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest (2002) 3.41
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest (2006) 2.64
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 2.55
Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One (2009) 2.47
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol (2004) 2.16
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2005) 1.71
Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res (2005) 1.64
Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem (2003) 1.63
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells. PLoS One (2012) 1.55
DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (2007) 1.54
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res (2010) 1.51
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res (2004) 1.46
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain (2010) 1.38
CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol (2005) 1.34
Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells (2013) 1.33
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol (2011) 1.30
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol (2006) 1.27
Characterization of stem cell-like cancer cells in immune-competent mice. Blood (2006) 1.19
A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjug Chem (2002) 1.19
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology (2007) 1.16
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother (2003) 1.16
Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology (2010) 1.16
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med (2012) 1.16
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 1.16
Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A (2007) 1.14
Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother (2008) 1.13
A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res (2005) 1.12
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother (2007) 1.08
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res (2007) 1.07
Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci U S A (2003) 1.06
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer (2010) 1.06
SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells. Carcinogenesis (2013) 1.05
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res (2005) 1.04
CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother (2008) 1.03
Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology (2006) 1.03
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer (2013) 1.03
Expression and roles of Slit/Robo in human ovarian cancer. Histochem Cell Biol (2011) 1.02
Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol (2003) 1.02
Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future (2010) 1.00
In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol (2006) 1.00
Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother (2004) 1.00
T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol (2012) 0.99
T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood (2005) 0.99
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res (2007) 0.98
Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology (2006) 0.97